CEA is used to monitor disease recurrence and therapeutic efficacy in colorectal cancer and gynecologic cancer such as endometrial cancer, ovarian cancer, cervical cancer, and vulvar cancer [20–26]. This evidence concerns the gene CEACAM5 and vulva cancer.